<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01129284</url>
  </required_header>
  <id_info>
    <org_study_id>AAAD9539</org_study_id>
    <nct_id>NCT01129284</nct_id>
  </id_info>
  <brief_title>Treatment of Resistant Nephrotic Syndrome With ACTH Gel (ACTHAR)</brief_title>
  <official_title>The Treatment of Resistant Nephrotic Syndrome With ACTH Gel (ACTHAR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the safety and effectiveness of ACTHAR Gel, when used to treat 15
      patients diagnosed with &quot;treatment resistant nephrotic syndrome.&quot;

      Nephrotic syndrome is a group of symptoms that includes low levels of protein in the blood,
      swelling of tissue (edema), especially around the eyes, feet and hands; and high plasma
      levels of cholesterol. It is caused by a variety of diseases and underlying disorders that
      damage the kidneys, resulting in excessive excretion of protein in the urine. These diseases
      damage the glomeruli, which are small blood vessels that filter wastes and excess water from
      the blood and pass them into the bladder as urine. As a result of protein loss in the urine,
      the blood is deficient in protein. Normal amounts of blood protein are needed to help
      regulate fluid throughout the body. Protein in the blood normally draws water from the
      tissues and into the bloodstream. When blood protein levels are low, the normal movement of
      water is reversed, and fluid is drawn from the blood and accumulates in the tissues. This
      excess tissue fluid causes the swelling and puffiness (edema) that is a symptom of nephrotic
      syndrome.

      Nephrotic syndrome is described as &quot;treatment resistant&quot; when a patient fails to achieve a
      sustained partial or complete remission after treatment with at least two first line
      therapies.

      The goal of this study is to determine whether injections of ACTHAR Gel (an FDA approved
      treatment for nephrotic syndrome) over a six month period will lead to a correction of
      treatment resistant nephrotic syndrome in these patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The nephrotic syndrome is characterized by heavy proteinuria, edema, hyperlipidemia, and a
      thrombotic tendency. Membranous nephropathy, focal segmental glomerulosclerosis, resistant
      minimal change disease, and Immunoglobulin A (IgA) nephropathy (also known as Berger's
      disease) are the common forms of idiopathic nephrotic syndrome in adults. Asymptomatic
      patients with idiopathic nephrotic syndrome may be treated with ACE inhibitors and /or
      angiotension receptor blockers to reduce proteinuria, with statins to treat hyperlipidemia,
      and diuretics to control edema.

      Patients with large amounts of proteinuria are refractory to such treatments and often
      require immunosuppressive medications to promote a remission of the proteinuria and the
      nephrotic syndrome and to prevent progressive renal failure. All such immunosuppressives have
      multiple potential serious side effects. Some patients either relapse after remissions of
      their proteinuria or are resistant to immunosuppressive therapy.

      A synthetic truncated analog of ACTH has been used in patients with the nephrotic syndrome in
      both uncontrolled trials and in a randomized controlled trial in membranous nephropathy. In
      uncontrolled studies it has led to sustained remissions of the nephrotic syndrome in multiple
      forms of idiopathic disease including membranous nephropathy and focal segmental
      glomerulosclerosis (FSGS). It has also led to reduction of total cholesterol, LDL
      cholesterol, Lpa, and elevations of HDL cholesterol. In a controlled randomized trial in
      membranous nephropathy it proved equivalent to an alternating monthly regimen of
      corticosteroids and an alkylating agent that is widely regarded as a first line therapy for
      this disease.

      This synthetic truncated analog of ACTH is not available in the US. ACTHAR gel is a natural,
      highly purified, porcine ACTH which is both available in the US and FDA approved for use in
      the nephrotic syndrome. Although ACTHAR gel has been used to treat large numbers of patients
      with multiple sclerosis and infantile paralysis annually, it has, however, been used in only
      small numbers of patients for the indication of the nephrotic syndrome.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Significant Reduction in Proteinuria to Remission Levels During the Treatment Period (Includes Complete and Partial Remission, as Defined in the Outcome Measure Description Below)</measure>
    <time_frame>6 months</time_frame>
    <description>Complete remission is defined as stable or improved renal function, serum creatinine &lt; or = 125% baseline, with proteinuria falling &lt;500 mg/day at month 6. Partial remission is defined as stable or improved renal function, serum creatinine &lt; or = 125% baseline, with 50% reduction in proteinuria and final proteinuria 500-3500 mg/day at month 6.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sustained Remissions up to 1 Year After Discontinuing Therapy</measure>
    <time_frame>Up to 1 year after treatment</time_frame>
    <description>Complete remission defined as stable or improved renal function, serum creatinine &lt; or = 125% baseline, with proteinuria falling &lt;500 mg/day at last follow-up visit (6 to 12 months post treatment). Partial remission defined as stable or improved renal function, serum creatinine &lt; or = 125% baseline, with 50% reduction in proteinuria and final proteinuria 500-3500 mg/day at last follow-up visit (6 to 12 months post treatment).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Treatment Resistant Nephrotic Syndrome</condition>
  <arm_group>
    <arm_group_label>Acthar gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with ACTHAR gel starting with 40 units given twice weekly subcutaneously for two weeks, then 80 units given twice weekly subcutaneously afterwards for a period of up to six months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACTHAR gel</intervention_name>
    <description>Patients will be treated with ACTHAR gel starting with 40 units given twice weekly subcutaneously for two weeks, then 80 units given twice weekly subcutaneously afterwards for a period of up to six months.</description>
    <arm_group_label>Acthar gel</arm_group_label>
    <other_name>H.P. Acthar gel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult nephrotic patients, at least 18 years of age

          2. Diagnosis of focal segmental glomerulosclerosis (FSGS), resistant or relapsing minimal
             change disease with failure to achieve a sustained partial or complete remission of
             the nephrotic syndrome after therapy with at least two first line therapies:
             corticosteroids and at least one other immunosuppressive regimen

          3. Diagnosis of membranous nephropathy with failure to achieve a sustained partial or
             complete remission of the nephrotic syndrome after therapy with at least two first
             line therapies: either the &quot;Ponticelli protocol&quot; of alternating months of pulse
             steroids followed by oral steroids and then an alkylating agent with each regimen
             repeated for six full months of therapy or a calcineurin inhibitor, cyclosporine or
             tacrolimus, and at least one other therapy

          4. Diagnosis of immunoglobulin A nephropathy (IgAN) with persistent nephrotic range
             proteinuria in patients on ACE inhibition or angiotension receptor blockers (ARB)
             therapy to reduce proteinuria

          5. Willing and able to sign informed consent

          6. Patients of childbearing age must agree to use birth control

        Exclusion Criteria:

          1. Patients under 18 years of age

          2. Patients unable to sign informed consent

          3. Patients having received rituximab or another monoclonal antibody within 6 months of
             the trial

          4. Patients of childbearing age who refuse to use birth control

          5. Patients with an estimated glomerular filtration rate (eGFR) less than 30
             ml/min/1.73m2

          6. Patients with other renal diseases (e.g. diabetic nephropathy, renal vascular disease)
             that would interfere with interpretation of the study.

          7. Patients with comorbid conditions that would interfere with completion of the trial
             (malignancies, congestive heart failure (CHF), recent myocardial infarction).

          8. Patients with known contraindications to the use of H.P. ACTHAR Gel, including:
             scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent
             surgery, history of or the presence of a peptic ulcer, congestive heart failure,
             uncontrolled hypertension, and allergies to pork or pork products.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerald B Appel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Bomback AS, Canetta PA, Beck LH Jr, Ayalon R, Radhakrishnan J, Appel GB. Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: a prospective trial. Am J Nephrol. 2012;36(1):58-67. doi: 10.1159/000339287. Epub 2012 Jun 19.</citation>
    <PMID>22722778</PMID>
  </results_reference>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2010</study_first_submitted>
  <study_first_submitted_qc>May 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2010</study_first_posted>
  <results_first_submitted>February 5, 2014</results_first_submitted>
  <results_first_submitted_qc>March 25, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 24, 2014</results_first_posted>
  <last_update_submitted>March 25, 2014</last_update_submitted>
  <last_update_submitted_qc>March 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Gerald B. Appel</investigator_full_name>
    <investigator_title>Professor of Clinical Medicine, Nephrology</investigator_title>
  </responsible_party>
  <keyword>Treatment Resistance</keyword>
  <keyword>Nephrotic Syndrome</keyword>
  <keyword>Focal Segmental Glomerulosclerosis</keyword>
  <keyword>lipoid nephrosis</keyword>
  <keyword>Membranous nephropathy</keyword>
  <keyword>IgA nephropathy</keyword>
  <keyword>proteinuria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Nephrotic Syndrome</mesh_term>
    <mesh_term>Nephrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenocorticotropic Hormone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>15 subjects with resistant glomerular diseases were enrolled and treated with ACTH gel (80 units subcutaneously twice weekly) for 6 months.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Membranous Nephropathy</title>
          <description>Subjects diagnosed with membranous nephropathy were treated with ACTH gel (80 units subcutaneously twice a week) for 6 months.</description>
        </group>
        <group group_id="P2">
          <title>FSGS/MCD</title>
          <description>Subjects diagnosed with focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD) were treated with ACTH gel (80 units subcutaneously twice a week) for 6 months.</description>
        </group>
        <group group_id="P3">
          <title>Immunoglobulin A (IgA) Nephropathy</title>
          <description>Subjects diagnosed with Immunoglobulin A (IgA) nephropathy (Berger's disease) were treated with ACTH gel (80 units subcutaneously twice a week) for 6 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Membranous Nephropathy</title>
          <description>Subjects diagnosed with membranous nephropathy</description>
        </group>
        <group group_id="B2">
          <title>FSGS/MCD</title>
          <description>Subjects diagnosed with focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD)</description>
        </group>
        <group group_id="B3">
          <title>IgA Nephropathy</title>
          <description>Subjects diagnosed with IgA nephropathy (Berger's disease)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Immunosuppressive therapy</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>steroids</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>steroids, cyclosporine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>steroids, cyclosporine, MMF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>steroids, cyclosporine, tacrolimus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>steroids, MMF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>steroids, MMF, cyclophosphamide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>steroids, tacrolimus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>steroids, tacrolimus, cyclosporine, MMF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cyclosporine, MMF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMF, cyclophosphamide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMF, tacrolimus, cyclosporine, rituximab</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>none</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Renal Function</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Impaired function: sCr range 1.6-2.9 mg/dl</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Preserved function: sCr range 0.6-1.2 mg/dl</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Preserved function: eGFR&gt;60 ml/min/1.73m2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Significant Reduction in Proteinuria to Remission Levels During the Treatment Period (Includes Complete and Partial Remission, as Defined in the Outcome Measure Description Below)</title>
        <description>Complete remission is defined as stable or improved renal function, serum creatinine &lt; or = 125% baseline, with proteinuria falling &lt;500 mg/day at month 6. Partial remission is defined as stable or improved renal function, serum creatinine &lt; or = 125% baseline, with 50% reduction in proteinuria and final proteinuria 500-3500 mg/day at month 6.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Membranous Nephropathy</title>
            <description>Subjects diagnosed with membranous nephropathy, treated with ACTH gel (80 units subcutaneously twice a week) for 6 months</description>
          </group>
          <group group_id="O2">
            <title>FSGS/MCD</title>
            <description>Subjects diagnosed with focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD), treated with ACTH gel (80 units subcutaneously twice a week) for 6 months</description>
          </group>
          <group group_id="O3">
            <title>IgA Nephropathy</title>
            <description>Subjects diagnosed with IgA nephropathy (Berger's disease), treated with ACTH gel (80 units subcutaneously twice a week) for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Significant Reduction in Proteinuria to Remission Levels During the Treatment Period (Includes Complete and Partial Remission, as Defined in the Outcome Measure Description Below)</title>
          <description>Complete remission is defined as stable or improved renal function, serum creatinine &lt; or = 125% baseline, with proteinuria falling &lt;500 mg/day at month 6. Partial remission is defined as stable or improved renal function, serum creatinine &lt; or = 125% baseline, with 50% reduction in proteinuria and final proteinuria 500-3500 mg/day at month 6.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sustained Remissions up to 1 Year After Discontinuing Therapy</title>
        <description>Complete remission defined as stable or improved renal function, serum creatinine &lt; or = 125% baseline, with proteinuria falling &lt;500 mg/day at last follow-up visit (6 to 12 months post treatment). Partial remission defined as stable or improved renal function, serum creatinine &lt; or = 125% baseline, with 50% reduction in proteinuria and final proteinuria 500-3500 mg/day at last follow-up visit (6 to 12 months post treatment).</description>
        <time_frame>Up to 1 year after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Membranous Nephropathy</title>
            <description>Subjects diagnosed with membranous nephropathy, treated with ACTH gel (80 units subcutaneously twice a week) for 6 months</description>
          </group>
          <group group_id="O2">
            <title>FSGS/MCD</title>
            <description>Subjects diagnosed with focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD), treated with ACTH gel (80 units subcutaneously twice a week) for 6 months</description>
          </group>
          <group group_id="O3">
            <title>IgA Nephropathy</title>
            <description>Subjects diagnosed with IgA nephropathy (Berger's disease), treated with ACTH gel (80 units subcutaneously twice a week) for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Remissions up to 1 Year After Discontinuing Therapy</title>
          <description>Complete remission defined as stable or improved renal function, serum creatinine &lt; or = 125% baseline, with proteinuria falling &lt;500 mg/day at last follow-up visit (6 to 12 months post treatment). Partial remission defined as stable or improved renal function, serum creatinine &lt; or = 125% baseline, with 50% reduction in proteinuria and final proteinuria 500-3500 mg/day at last follow-up visit (6 to 12 months post treatment).</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Membranous Nephropathy</title>
          <description>Subjects diagnosed with membranous nephropathy, treated with ACTH gel (80 units subcutaneously twice a week) for 6 months</description>
        </group>
        <group group_id="E2">
          <title>FSGS/MCD</title>
          <description>Subjects diagnosed with focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD), treated with ACTH gel (80 units subcutaneously twice a week) for 6 months</description>
        </group>
        <group group_id="E3">
          <title>IgA Nephropathy</title>
          <description>Subjects diagnosed with IgA nephropathy (Berger's disease), treated with ACTH gel (80 units subcutaneously twice a week) for 6 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>exacerbation of diabetes</sub_title>
                <description>Subjects 1 and 2, both with membranous nephropathy (MN) and previous diagnoses of diet-controlled diabetes, had worsened glycemic control prompting initiation of oral hypoglycemic therapy.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Cushingoid response</sub_title>
                <description>Cushingoid response: includes weight gain, Cushingoid facies, and increased blood pressure</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Increased skin pigmentation</sub_title>
                <description>resolved within 4 weeks of discontinuing drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Andrew S. Bomback, MD, MPH</name_or_title>
      <organization>Columbia University Medical Center</organization>
      <phone>212-305-0320</phone>
      <email>asb68@columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

